Introduction {#Sec1}
============

Essential hypertension is not only one of the main causes but also one of the clinical manifestations of cardiovascular diseases. It is a highly complex disease that can be induced by both environmental and genetic factors \[[@CR1], [@CR2]\]. The mechanism of essential hypertension is still unclear. There are still no precise pre-diagnosis methods or efficient treatment options for essential hypertension \[[@CR2]--[@CR4]\]. Thus, it is necessary to identify specific markers for essential hypertension.

MicroRNA is a kind of small non-coding RNA with about 20 bp in length that can regulate gene expression at the post-transcriptional level \[[@CR4]--[@CR6]\]. Previous studies demonstrate that microRNAs can be used as diagnostic biomarkers for hypertension and cardiovascular diseases \[[@CR2], [@CR4]\]. The abnormal expression of microRNAs in tissues and body fluids has also been reported \[[@CR2], [@CR4], [@CR6]\]. It is also found that there were 27 microRNAs differentially expressed in patients with essential hypertension and that the relationship between hmcv-miR-UL122 and hypertension was identified \[[@CR7]\]. In addition, the increased expression of miR-505 may play important roles in essential hypertension \[[@CR8]\]. Tissue-based studies also illustrate that several microRNAs play remarkable roles in hypertension, such as miR-181a \[[@CR1], [@CR9]\], miR-1, miR-21, miR-9 and miR-126 \[[@CR10], [@CR11]\].

MicroRNA array and quantitative PCR are two main techniques for detection and examination of microRNAs \[[@CR2]--[@CR4], [@CR6]\]. The microRNA profile of hypertension has been investigated. However, different microRNA biomarker sets were obtained due to the diversity of experiment methods and research subjects \[[@CR1]--[@CR4]\]. More microRNA markers for essential hypertension remain to be identified. In this study, we screened the microRNA profile of essential hypertension in Uyghur population. Our study may provide experimental evidence for investigating the possible role and mechanism of microRNAs in essential hypertension.

Materials and methods {#Sec2}
=====================

Sample collection and processing {#Sec3}
--------------------------------

Eight Uyghur subjects aged between 30 and 40 years old were recruited. Four subjects, including 2 males and 2 females, with untreated essential hypertension were included in the hypertension group. Inclusion criteria: 1) blood pressure should meet one of the following criteria: Sitting blood pressure was higher than or equal to 140/90 mill Hg (1 mmHg = 0.133 kPa) measured by Mercury sphygmomanometer; and/or, average daily blood pressure was higher than or equal to 135/85 mill Hg by 24-h ambulatory blood pressure monitor; 2) patients diagnosed with essential hypertension for the first time; 3) patients were untreated. Exclusion criteria: 1) patients with secondary hypertension; 2) patients with cardiac function III, IV, coronary heart disease, severe pulmonary insufficiency, rheumatic diseases, diabetes, endocrine disorders, severe liver or kidney dysfunction, stroke, peripheral arterial disease, or, mental illness; 3) pregnant or lactating women. Four age and gender matched healthy individuals with normal blood pressure (2 males and 2 females) were included in the control group. Healthy subjects did not smoke and had no history of cancer, diabetes, kidney failure, stroke or peripheral arterial disease. For verification of microRNA expression, another 15 patients with essential hypertension (8 males and 7 females) and 15 healthy individuals (4 males and 11 females) were included. The inclusion and exclusion criteria were same as above.

All subjects were fasted before sampling and sampled at the same time in the morning. They were asked to sit still for 10 min before blood collection. Totally, 3 mL of peripheral blood was collected from each subject and the plasma was then isolated.

All subjects or their families signed the informed consent. The study was approved by Ethical committee of Xinjiang Medical University.

RNA extraction and miRNA microarray analysis {#Sec4}
--------------------------------------------

Total RNAs were extracted from plasma using mirVana PARIS kit (Ambion-1556) and quantified by NanoDrop ND-2000 (Thermo Scientific). RNA quality was checked by Bioanalyzer 2100 (Agilent, G2939A). MicroRNA expression was detected by Agilent Human miRNA Microarray (Agilent, 8\*60 K, ID070156). RNAs were hybridized with the array in hybridization oven (Agilent, G2545A). Then, array signals were scanned by Agilent Scanner (Agilent, G2505C). All processes were performed in accordance with the standard guidelines provided by the manufacturer.

The signals were then analyzed by Feature Extraction software (version10.7.1.1, Agilent Technologies). Raw data was obtained, and normalized with the quartile algorithm using Genespring software (version 12.5; Agilent Technologies) to calculate the microRNA expression. MicroRNAs with fold changes greater than two and a *p*-value below 0.05 were defined as differentially expressed.

MicroRNA annotation {#Sec5}
-------------------

MicroRNAs were clustered using the Hierarchical Clustering method. The chromosome loci of microRNAs were annotated by miRBase (<http://www.mirbase.org/>) and HGNC (Hugo Gene Nomenclature Committee) (<http://www.genenames.org/>). Cytogenetic locations of microRNAs and OMIM (Online Mendelian Inheritance in Man) record of essential hypertension were retrieved from OMIM database (<http://www.omim.org/>).

Target gene prediction, GO annotation and pathway analysis {#Sec6}
----------------------------------------------------------

Target genes of microRNAs were predicted using three databases of Targetscan, (<http://www.targetscan.org/>), microRNAorg, (<http://www.microrna.org/>), and pita, (<https://genie.weizmann.ac.il/pubs/mir07/>), respectively. The resulted genes shared by three databases were selected and then analyzed using Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway. Furthermore, genes were clustered according to the annotation information by DAVID analysis tool (<https://david.ncifcrf.gov/>).

Quantitative real-time PCR {#Sec7}
--------------------------

Quantitative real-time PCR (qPCR) was conducted to verify microRNA expression. MicroRNAs were extracted using QIAzol Lysis Reagent (QIAGEN, 5346994), miRNeasy Serum/Plasma Spike-In Control (QIAGEN, 219610) and miRNeasy Serum/Plasma Kit (QIAGEN,217184). cDNA was prepared using miScript II RT Kit (QIAGEN, 218161). MicroRNA expression was detected using miScript SYBR Green PCR Kit (QIAGEN, 218073) on ABI7500 (ABI). Four pairs of Primers were used in qPCR assays, including hsa-miR-1183 (CD201--0149, TIANGEN BIOTECH), hsa-miR-198 (CD201--0085, TIANGEN BIOTECH), hsa-miR-30e-5p (CD201--0340, TIANGEN BIOTECH) and hsa-miR-144-3p (CD201--0011, TIANGEN BIOTECH). miRNA39 was used for normalization in the qRT-PCR assays. The relative gene expression was calculated with 2^-ΔΔCt^ method.

Statistical analysis {#Sec8}
--------------------

Prism statistical software (GraphPad Software Inc) was used for data analysis. Difference in microRNA expression between essential hypertension group and control group was analyzed by student t-test. A value of *p* ≤ 0.05 was considered to be statistically significant.

Results {#Sec9}
=======

The expression profile of microRNAs in the essential hypertension group {#Sec10}
-----------------------------------------------------------------------

Totally, 257 microRNAs that showed differential expression between patients with essential hypertension and the control group were obtained (Table [1](#Tab1){ref-type="table"}). The number of up-regulated microRNAs (161) was higher than that of down-regulated microRNAs (96) (Table [1](#Tab1){ref-type="table"}). Furthermore, fold change distribution of the differentially expressed microRNAs showed distinct pattern. Up-regulated microRNAs changed much more than the down-regulated microRNAs (Fig. [1](#Fig1){ref-type="fig"}). The change of hsa-miR-1183 expression (up-regulated, fold change = 44.41) and hsa-miR-30e-5p expression (down-regulated, fold change = 24) were the most significant (Table [2](#Tab2){ref-type="table"}). Cluster analysis classified samples into separate groups based on the microRNA expression in each sample. The microRNA expression of patients in the essential hypertension group was obviously different from that of healthy controls (Fig. [2](#Fig2){ref-type="fig"}). Overall, nearly 2/3 microRNAs showed higher level in the essential hypertension samples (Fig. [2](#Fig2){ref-type="fig"}).Table 1Number of differentially expressed microRNAClassificationTotalUPDOWNDifferentially expressed miRNA25716196Differentially expressed miRNA that possess target genes472423Fig. 1Fold change distribution of differentially expressed microRNA. **a** The left distribution chart illustrates fold changes of all differentially expressed microRNAs. **b** The right chart shows fold change of differentially expressed microRNAs that possess target genes. Pink represents the down-regulated microRNAs. Blue represents the up-regulated miRNAsTable 2List of screened differentially expressed microRNAsUp-regulated miRNA*p*-valueFold changeDown-regulated miRNA*P*-valueFold Change**hsa-miR-1183**1.07E-0744.41**hsa-miR-30e-5p**0.00183924.00**hsa-miR-198**3.88E-0442.16**hsa-miR-144-3p**0.04230319.41hsa-miR-9360.00190935.16hsa-miR-92b-3p0.00141617.29hsa-miR-6010.00184630.83hsa-miR-483-3p0.00241415.37hsa-miR-1224-5p5.42E-0429.21hsa-miR-1260a0.00671614.46hsa-miR-659-3p7.51E-0425.28hsa-miR-1224-3p0.00225913.07hsa-miR-11823.07E-0523.79hsa-miR-129-2-3p0.0269739.70hsa-miR-5570.02026722.84hsa-miR-18259.39E-049.28hsa-miR-877-5p9.32E-0819.28hsa-miR-22-3p1.44E-059.04hsa-miR-5750.04536117.53hsa-miR-766-3p3.21E-078.89hsa-miR-371a-5p0.0365714.30hsa-miR-9330.0077227.57hsa-miR-7650.00759313.26hsa-miR-12811.49E-047.36hsa-miR-874-3p0.02992612.98hsa-miR-149-5p6.17E-046.02hsa-miR-4988.55E-0512.58hsa-miR-223-3p0.0385064.91hsa-miR-5640.0357059.26hsa-miR-361-5p0.0129614.29hsa-miR-4842.52E-087.34hsa-miR-92a-3p0.0164144.19hsa-miR-769-3p0.0133645.92hsa-miR-494-3p0.0022353.56hsa-miR-6230.0042445.07hsa-miR-30d-5p4.70E-043.38hsa-miR-378a-3p0.0313185.02hsa-miR-574-5p0.0364953.19hsa-miR-13230.0403023.15hsa-miR-1238-3p6.79E-042.68hsa-miR-516a-5p0.0405042.53hsa-miR-9405.81E-042.64hsa-miR-526b-5p0.0419222.48hsa-miR-1237-3p0.0123152.23hsa-miR-939-5p0.0035952.42hsa-miR-1234-3p3.41E-042.09hsa-miR-6360.0296362.08------Four microRNAs of interest are shown in bold. All microRNAs screened above have a fold change of at least 2 and their target genes could be searched in databaseFig. 2Hierarchical clustering analysis of circulating microRNA expression data from samples of essential hypertension patients (*n* = 4) and the healthy (*n* = 4). MicroRNA expression data are illustrated by the heat map after cluster analysis. X-axis represents sample names. Y-axis represents micro-RNA names. Each lane indicates microRNA expression. The left our lanes represents the microRNA expression in the essential hypertension group and the right four lanes represents the microRNA expression in the control group. Color bar shows the relative expression. Down-regulated microRNAs are shown in green and up-regulated microRNAs are shown in red

Target gene identification and filteration of candidate microRNA markers {#Sec11}
------------------------------------------------------------------------

Target genes of the microRNAs were predicted by microRNAorg, PITA and TargetScan. Target genes that were simutaneously predicted by these three tools were selected (Fig. [3](#Fig3){ref-type="fig"} and Fig. [4](#Fig4){ref-type="fig"}). In total, 6580 target genes were obtained (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We further screened out 47 microRNAs that had target genes (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The number of up-regulated and down-regulated microRNAs that had target genes was almost equal (Table [1](#Tab1){ref-type="table"}). Hsa-miR-765, hsa-miR-940, hsa-miR-1183, hsa-miR-557 and hsa-miR-939-5p had over 300 target genes. Hsa-miR-765 had the largest number of target genes (475) (Table [3](#Tab3){ref-type="table"}).Fig. 3Chromosome loci of microRNAs and the number of target genes. The right column represents the number of differentially expressed microRNAs located in different chromosome. The left column represents the number of genes targeted by those miRNAsFig. 4Chromosome loci of target genes and microRNA numbers with target genes. The number of target genes located in each chromosome and the number of miRNAs regulating those genes were shownTable 3Chromosome loci and OMIM disease annotation of microRNAMicroRNAChr_locationNumber of target genesMIM NumberMIM Titlehsa-miR-11821q42.2145\#145500/ + 106,150HYPERTENSION, ESSENTIAL/ ANGIOTENSINOGEN; AGThsa-miR-30e-5p1p34.273----hsa-miR-5571q24.2306\*131210/ \*182330/ \#145500SELECTIN E; SELE/ ATPase, Na+/K+ TRANSPORTING, BETA-1 POLYPEPTIDE; ATP1B1/ HYPERTENSION, ESSENTIALhsa-miR-7651q23.1475----hsa-miR-92b-3p1q22131\#151660LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2hsa-miR-149-5p2q37.3153----hsa-miR-9332q31.111----hsa-miR-1224-3p/5p3q27.1260----hsa-miR-1983q13.33169----hsa-miR-5643p21.3153\*160790MYOSIN, LIGHT CHAIN 3, ALKALI, VENTRICULAR, SKELETAL, SLOW; MYL3hsa-miR-574-5p4179----hsa-miR-5754q21.22105----hsa-miR-378a-3p5q3286----hsa-miR-874-3p5q31.2142\#614495/ \*605775PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D/\
KELCH-LIKE 3; KLHL3hsa-miR-877-5p6p21.33170----hsa-miR-11837347----hsa-miR-1234-3p816----hsa-miR-30d-5p8q24.2269----hsa-miR-939-5p8q24.3305\#103900/ \*608216GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA/ COMM DOMAIN-CONTAINING PROTEIN 5; COMMD5hsa-miR-6019q33.370----hsa-miR-93610q25.1221\*601568ADDUCIN 3; ADD3hsa-miR-1237-3p11129----hsa-miR-129-2-3p11p11.226\#125853DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDMhsa-miR-483-3p11p15.534\#125852/ \*191290DIABETES MELLITUS, INSULIN-DEPENDENT, 2/ TYROSINE HYDROXYLASE; THhsa-miR-62313q32.3231----hsa-miR-1260a14134----hsa-miR-494-3p14q32.3189----hsa-miR-48416p13.11133\*603234/ \#264800ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 6; ABCC6/ PSEUDOXANTHOMA ELASTICUM; PXEhsa-miR-94016p13.3393\#173900/ \*610886/ \*601313POLYCYSTIC KIDNEY DISEASE 1; PKD1/ ESSENTIAL MEIOTIC ENDONUCLEASE 1, S. POMBE, HOMOLOG OF, 2; EME2/ POLYCYSTIN 1; PKD1hsa-miR-144-3p17q11.243\*163730/ \#162200/ \#145500NITRIC OXIDE SYNTHASE 2A; NOS2A/ NEUROFIBROMATOSIS, TYPE I; NF1/ HYPERTENSION, ESSENTIALhsa-miR-22-3p17p13.397----hsa-miR-63617q25.1163----hsa-miR-1238-3p1951----hsa-miR-132319q13.42157----hsa-miR-371a-5p19q13.42183----hsa-miR-49819q13.42188----hsa-miR-516a-5p19q13.4212----hsa-miR-526b-5p19q13.42115----hsa-miR-769-3p19q13.32122+ 107,741APOLIPOPROTEIN E; APOEhsa-miR-18252040----hsa-miR-12812212----hsa-miR-659-3p22q13.1284----hsa-miR-92a-3p13q31.3/Xq26.2165----hsa-miR-223-3pXq1262----hsa-miR-361-5pXq21.292----hsa-miR-766-3pXq24139----Chr_location, chromosome locus of microRNA. OMIM, Online Mendelian Inheritance in Man. \* indicates that this record is a gene; \# indicates that this is a descriptive record, often a phenotype, not a unique locus. + indicates that this record contains a description of the genes and phenotypes of known sequences

Functional classification and pathway analysis of the target genes {#Sec12}
------------------------------------------------------------------

The biological functions of the target genes were analyzed by GO. Most target genes were involved in the regulation of transcription, signal transduction, organismal development and cell adhesion (Additional file [2](#MOESM2){ref-type="media"}: Figure S2A). The number of target genes in cytoplasm and nucleus was almost equal (Additional file [2](#MOESM2){ref-type="media"}: Figure S2B). Over half of the target genes (53.8%) had protein binding function, and about 40% of the genes may play roles in zinc-ion binding (17.5%) or metal-ion binding (23.9%) (Additional file [2](#MOESM2){ref-type="media"}: Figure S2C).

The target genes were classified into different functional groups based on GO-terms. It is well worth noting that most of genes were enriched in ion binding group (ES = 3.46) and transcription regulation group (ES = 3.44). Target genes involved in cell fraction and cell adhesion were enriched with an enrichment score of 5.55 and 4.33, respectively. In addition, pathway analysis was performed to analyze the signal pathways that target genes or microRNAs may participate in. We found that the target genes were mainly involved in cancer pathways, MAPK pathway, regulation of actin cytoskeleton and focal adhesion (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Pathway analysis that target genes are involved in. The x-axis represents the number of genes involved in corresponding pathway. The y-axis represents names of the top 19 pathways

Cytogenetic location and OMIM annotation of the microRNAs {#Sec13}
---------------------------------------------------------

Cytogenetic location of the 47 microRNA candidates were analyzed. Most of them were located at chromosome 19 (40 microRNAs) and chromosome 1 (45 microRNAs) (Table [3](#Tab3){ref-type="table"}). No microRNA was found on chromosome 12, 15, 18 or Y. Moreover, OMIM records of the patients with essential hypertension were evaluated. Totally, 13 OMIM records about essential hypertension were obtained. The records illustrated the relationship between microRNAs and disease status (Table [3](#Tab3){ref-type="table"}). Hsa-miR-1182, hsa-miR-557 and hsa-miR-144-3p showed a direct correlation with essential hypertension (OMIM ID \#145500). Moreover, miR-92b-3p, miR-939-5p, and miR-769-3p were annotated with lipodystrophy, glucocorticoid and apolipoprotein E, which are hypertension-related indicators.

Verification of the potential microRNA markers and microRNA-gene interaction {#Sec14}
----------------------------------------------------------------------------

Four microRNA candidates with significant expression change were verified by qPCR. MiR-198 and miR-1183 showed a higher expression in patients with essential hypertension while miR-30e-5p and miR-144-3p showed lower expression (Fig. [6](#Fig6){ref-type="fig"}). Fold change of microRNAs (miR-198, miR-1183, miR-30e-5p and miR-144-3p) measured by qPCR was in accordance with the results of microRNA array (Table [4](#Tab4){ref-type="table"}). In order to explore the relationship between microRNAs and target genes, a microRNA-gene interaction network was constructed (Fig. [7](#Fig7){ref-type="fig"}). Target genes of the four microRNAs were selected with a tougher criteria. Target genes were graded using miRBase database firstly and then the genes with scores of more than 80 were selected. Altogether, 33 target genes were obtained. MiR-144-3p shared 21 target genes with miR-30e-5p, while it didn't share any target gene with miR-198 (Fig. [7](#Fig7){ref-type="fig"}). MiR-1183 and miR-198 both regulated ARFGAP2. MiR-1183 and miR-144-3p both targeted MMGT1, ST6GALNAC3 and ZBTB21.Fig. 6Quantitative expression analysis of differentially expressed microRNA by qRT-PCR. Control: healthy samples; HP: essential hypertension samples. Relative expressions of (**a**) miRNA198, (**b**) miRNA1183, (**c**) miRNA30e-5p, and (**d**) miRNA144-3p were shown. \*\*\*: *p*-value\< 0.01, \*\*: *p*-value\< 0.05Table 4Fold change of selected microRNAsmiRNAMicroarray fold changeqPCR fold changeChangemiRNA19842.161.87UpmiRNA118344.411.53UpmiRNA30e-5p25.001.45DownmiRNA144-3p19.411.87DownFig. 7Interaction network of microRNAs and target genes. Red dot represents the four microRNAs of interest that show the most significant expression changes in essential hypertension group. Light blue dot represents target genes of microRNAs. Grey lines represent the interaction between the microRNAs and the target genes

Discussion {#Sec15}
==========

In this study, we identified 257 differentially expressed microRNAs from 4 Uyghur patients (from Xinjiang, China) with essential hypertension and constructed a candidate microRNA biomarker set of 47 microRNAs. To the best of our knowledge, this study is the first report to screen microRNA markers of essential hypertension in Uyghur population of Xinjiang, China. Our results add new information to the potential microRNA markers of essential hypertension.

Among the 47 microRNAs, the number of up-regulated and down-regulated microRNAs was almost equal. However, we found that the expression of up-regulated microRNAs changed more significantly. Compared with the microRNA profiles of hypertension reported by previous studies \[[@CR2]--[@CR4]\], many new microRNAs were identified in this study. The difference may be due to the complexity of hypertension or the differences in sampling population or methods \[[@CR2], [@CR4]\].

Previous studies have shown that essential hypertension may be caused by genetic factors \[[@CR1], [@CR2]\]. Here, we found that the microRNAs were mostly located on chromosome 1 and chromosome 19. Five miRNAs located at different loci of chromosome 1 and seven miRNAs located at chromosome 19, five of which located at the same locus (19q13.42). Further analysis through the OMIM database revealed that miR-1182 was annotated with angiotensinogen, a protein related to essential hypertension \[[@CR4], [@CR8]\]. Moreover, miR-557 was related to ATPase and Na^+^/K^+^ transport, which play important roles in the blood pressure regulation \[[@CR12], [@CR13]\]. miR-769-3p was annotated with apolipoprotein, a molecule that is closely related to cardiac diseases \[[@CR14]\]. These results demonstrate that the idenfied microRNAs are related with the metabolic processes of essential hypertension, indicating that these microRNAs may be involved in the development of essential hypertension.

Target genes were clustered into 8 groups by functional annotation and most of them were enriched in metal ion binding and transcription regulation (Table [5](#Tab5){ref-type="table"}). Abnormal Ca^2+^/Na^+^ is one of the common phenomena in hypertension and cardiovascular diseases \[[@CR12]\]. Annotation analysis both in microRNAs and target genes showed a tendency in ATP and mineral ions metabolism. This suggests that these microRNAs may be used as potential diagnostic markers. Further studies on the role and mechanism of microRNAs in essential hypertension are needed.Table 5GO classification of target genesEnrichment ScoreTermCount%P-value5.55GO:0000267\~cell fraction1178.932.35E-06GO:0005624\~membrane fraction937.102.56E-06GO:0005626\~insoluble fraction957.253.76E-064.90GO:0030424\~axon312.376.00E-07GO:0043005\~neuron projection493.743.38E-06GO:0042995\~cell projection725.509.96E-044.33GO:0007156\~homophilic cell adhesion322.443.32E-09GO:0016337\~cell-cell adhesion403.055.08E-05cell adhesion503.821.66E-04GO:0007155\~cell adhesion725.500.002747GO:0022610\~biological adhesion725.500.0028573.46GO:0046872\~metal ion binding36728.021.88E-05zinc-finger16012.212.68E-05GO:0043169\~cation binding36728.024.67E-05GO:0043167\~ion binding37028.247.72E-05zinc18814.354.53E-04metal-binding24318.559.94E-043.44transcription regulation19514.893.24E-07Transcription19815.113.92E-07nucleus36427.797.14E-07GO:0030528\~transcription regulator activity15211.606.06E-05GO:0045449\~regulation of transcription23417.862.32E-04GO:0006350\~transcription19114.586.37E-04GO:0043565\~sequence-specific DNA binding654.960.002591GO:0003700\~transcription factor activity957.250.0046763.22GO:0014069\~postsynaptic density181.376.30E-06GO:0045202\~synapse483.662.05E-05GO:0030054\~cell junction614.669.09E-05cell junction473.593.04E-04synapse292.215.96E-04GO:0044456\~synapse part292.210.008233.20ubl conjugation pathway624.731.05E-05GO:0051603\~proteolysis involved in cellular protein catabolic process705.341.00E-04GO:0044257\~cellular protein catabolic process705.341.15E-04GO:0043632\~modification-dependent macromolecule catabolic process665.042.46E-04GO:0019941\~modification-dependent protein catabolic process665.042.46E-04GO:0030163\~protein catabolic process705.342.89E-04GO:0006511\~ubiquitin-dependent protein catabolic process342.603.62E-04GO:0044265\~cellular macromolecule catabolic process745.650.0028873.12kinase806.112.92E-06nucleotide-binding15912.141.50E-05transferase13210.087.49E-05atp-binding1259.541.39E-04GO:0006796\~phosphate metabolic process1027.791.62E-04GO:0006793\~phosphorus metabolic process1027.791.62E-04GO:0006468\~protein amino acid phosphorylation735.574.73E-04GO:0017076\~purine nucleotide binding17813.598.59E-04GO:0016310\~phosphorylation836.349.76E-04GO:0032553\~ribonucleotide binding17012.980.001314GO:0032555\~purine ribonucleotide binding17012.980.001314serine/threonine-protein kinase433.280.001333GO:0001883\~purine nucleoside binding14811.300.003017GO:0030554\~adenyl nucleotide binding14611.150.003068GO:0000166\~nucleotide binding19915.190.0037GO:0001882\~nucleoside binding14811.300.003985GO:0005524\~ATP binding13710.460.004062GO:0032559\~adenyl ribonucleotide binding13810.530.004694

In our study, target genes related to cell adhesion and junction were enriched into two clusters. Researchers have found that miR-92a may play a role in mediating cell-to-cell communication \[[@CR15]--[@CR17]\]. The miR-1 may affect the genes of gap-junction channels \[[@CR12], [@CR18]\]. Our results reveal that microRNAs may participate in regulating cell communications in essential hypertension. Pathway analysis also supported their role in cell to cell communication. Genes in this pathway are involved in focal adhesion and regulation of actin cytoskeleton and adherence junction. However, sources of microRNAs in plasma are various. Apoptotic, necrotic cell death and active secretion all result in detectable microRNAs in plasma \[[@CR19]\].

MiR-198 and miR-1183 were the two most significantly up-regulated microRNAs according to the microarray results, while miR-30e-5p and miR-144-3p were the two most significantly down-regulated microRNAs. QPCR further confirmed the microarray results. However, the fold change of microRNA expression measured by qPCR was not as significant as that by microarray. Li et al. found that miR-1183 was a potential diagnostic marker for rheumatic heart disease \[[@CR20]\]. High expression level of miR-198 is reported in acute coronary syndromes \[[@CR21]\]. miR-30e-5p is found to suppress the expression of hypertension related gene ADRA2A in human endothelial cells \[[@CR22]\]. miR-144-3p regulates cholesterol homeostasis and is identified as a potential therapeutic target of atherosclerosis and acute myocardial infarction \[[@CR23]\]. However, how are these four microRNAs involved in essential hypertension are unclear. The significant changes of their expression in this research may pave a way for further study.

Interaction analysis can greatly help us to understand the relationship of microRNAs with target genes. One microRNA may regulate multiple genes, and one gene might be regulated by different microRNAs \[[@CR3]--[@CR5]\]. In this study, the target genes of miR-198, miR-1183, miR-30e-5p and miR-144-3p were predicted and a microRNA-gene interaction network was constructed. Totally, 33 target genes were obtained. However, functional analysis and validation of the target genes are not performed and needs further study.

This study has some limitations. First, this study focused on Uyghur subjects from Xinjiang, China. Thus, the results of this study may lack representativeness for the general population. Second, the sample size was relatively small. Third, the number of differentially expressed microRNAs validated by qPCR was small. Fourth, the function of the 33 target genes of miR-1183, miR198, miR144-3p and miR-30e-5p was not further analyzed. Further studies are warranted.

In conclusion, we constructed a reference microRNA pool of essential hypertension and obtained a set of circulating microRNAs, which may be used as potential biomarkers for essential hypertension. These microRNAs showed a remarkable correlation with mineral ion metabolism and cellular communication. Four microRNAs (miR-1183, miR-198, miR-30e-5p and miR-144-3p) that showed most prominent change were further verified. A regulatory network between these microRNAs and their target genes was also constructed, which may provide experimental evidence for further study of the mechanism of essential hypertension.
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================

 {#Sec16}

Additional file 1:**Figure S1.** Target genes prediction by three microRNA databases**.** Targetscan (<http://www.targetscan.org/>), microRNAorg (<http://www.microrna.org/>), and, pita (<https://genie.weizmann.ac.il/pubs/mir07/>) was used (TIF 99 kb) Additional file 2:**Figure S2.** GO analysis**.** (A) Target gene coverage of GO biological process term. (B) Target gene coverage of GO cellular component terms. (C) Target gene coverage of GO molecular function terms (TIF 503 kb)
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